ArticleCancer medicine2015
HER2 as a target in invasive urothelial carcinoma.
Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- HER2 expression in urothelial carcinoma, a systematic literature review.Frontiers in oncology · 2022Pooled it
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Association of molecular subtypes based on GATA3, KRT5, and P16 expression with clinicopathological features and prognosis in upper tract urothelial carcinoma.World journal of urology · 2026Article
- Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.Translational andrology and urology · 2026Article
- Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Impact of immune microenvironment on immune checkpoint inhibitor response in HER2-overexpressing urothelial carcinoma.Discover oncology · 2026Article
- Correlation analysis of HER2 expression with clinicopathological features and prognosis based on data from 444 patients with urothelial carcinoma.BMC urology · 2026Article
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Case Report: Complete metabolic responses to trastuzumab-deruxtecan in HER2-altered solid tumors: two illustrative cases.Frontiers in immunology · 2026Article
- Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.Cancer research communications · 2025Article
- Expression of HER2 in urothelial carcinoma and its significance.Current urology · 2025Article
- The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.Journal of translational medicine · 2025Article
- Prevalence and Clinical Outcomes of Human Epidermal Growth Factor Receptor 2 Expression in Patients With Advanced Urothelial Carcinoma.World journal of oncology · 2025Article
- Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy.Biological procedures online · 2025Article
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.Targeted oncology · 2024Article
- Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.Molecules (Basel, Switzerland) · 2024Review
- Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.Medicina (Kaunas, Lithuania) · 2024Review
- Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics.Frontiers in molecular biosciences · 2024Article
- Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.Frontiers in pharmacology · 2024Article
- Expression and clinicopathologic significance of HER2 and PD-L1 in high grade urothelial carcinoma of the urinary tract.International journal of clinical and experimental pathology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥ 2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), DNA copy number, mRNA expression, and mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival. ERBB2 mutation was determined by hotspot sequencing. mRNA expression was assessed using NanoString counting. Association of overall survival (OS) and HER2 status was assessed by a Cox regression model. NIH-3T3 cells containing HER2 V777L were assessed for growth, invasion, and HER2 kinase activation. In all, 22% of Spanish and 4% of Greek cohorts had 3+ HER2 staining by IHC. FISH amplification was identified in 20% of Spanish and 4% of Greek cohorts. Kappa coefficient between FISH and IHC was 0.47. HER2 status was not associated with OS in univariate (Spanish P = 0.34; Greek P = 0.11) or multivariate (Spanish P = 0.49; Greek P = 0.12) analysis. HER2-positive tumors expressed higher levels of HER2 mRNA than HER2-negative tumors (P < 0.001). HER2 mutations (V777L and L755S) were identified in two (2%) patients. In vitro analysis of V777L results in transformation of NIH-3T3 cells, leading to increased growth, invasion on soft agar, and HER2 kinase constitutive activation. In summary, HER2 overexpression or amplification in the primary tumor did not predict OS in patients with metastatic UC. HER2 positivity rates can differ between different populations. Further trials in genomically screened patients are needed to assess HER2-targeted therapies in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.